Mostrando 4 resultados de: 4
Filtros aplicados
Publisher
Revista Latinoamericana de Hipertension(2)
Archivos Venezolanos de Farmacologia y Terapeutica(1)
Cardiology Research and Practice(1)
Área temáticas
Enfermedades(2)
Farmacología y terapéutica(2)
Economía(1)
Fisiología humana(1)
Historia de América del Norte(1)
C-reactive protein: Clinical and epidemiological perspectives
ReviewAbstract: An important etiopathogenic component of cardiovascular disease is atherosclerosis, with inflammatioPalabras claves:Autores:Añez-Ramos R., Apruzzese V., Chávez-Castillo M., Martínez M.S., Rojas-Quintero J., Salazar-Vílchez J., Silva C., Toledo A.C., Torres Y., Valmore BermúdezFuentes:scopusPharmacologic treatment of obesity: Present, past and future
ReviewAbstract: Obesity is a chronic, stigmatized and costly disease that is rarely curable and is increasing in prePalabras claves:body mass index, Energetic balance, Noradrenegic agents, obesity, Orlistat, Serotoninergic agents, SibutraminAutores:Amell A., Bermúdez F.A., Cabrera M., Leal E.M., Mengual-Moreno E., Rodriguez M., Silva C., Toledo A., Valdelamar L., Valmore BermúdezFuentes:scopusLipid profile reference intervals in individuals from Maracaibo, Venezuela: An insight from the Maracaibo City Metabolic Syndrome prevalence study
ArticleAbstract: Objectives: Cardiovascular diseases are the main cause of death in adults worldwide. Dyslipidemias aPalabras claves:Cardiovascular disease, dyslipidemia, lipid profile, Reference intervalsAutores:Aguirre M.A., Añez-Ramos R., Angulo V., Arráiz N., Bello L.M., Carem Prieto, Fortul Y., González M.C., Linares S., Marcano R.P., Naguib A., Pacheco E., Ponce C.C., Rojas-Quintero J., Salazar-Vílchez J., Silva C., Toledo A.C., Torres Y., Valmore Bermúdez, Villalobos M.Fuentes:googlescopusSerum levels of lipoprotein(a) and its behavior in the state of Zulia: 10 Years of research
ReviewAbstract: Lipoprotein Lp(a) is considered one of the most important independent risk factors for atherosclerotPalabras claves:Cardiovascular disease, Coronary artery disease, Hormone replacement therapy, lipoprotein(a), myocardial infarction, Physical activity, risk factorAutores:Amell A., Añez-Ramos R., Arias F.B., Arráiz N., Cabrera M., Cano-Ponce C., Cruz S., González M.C., Mejías J.C., Mengual-Moreno E., Nava A., Rojas-Quintero J., Silva C., Sorell G L., Souki-Rincón A., Toledo A.C., Torres W., Torres Y., Valmore BermúdezFuentes:scopus